ClinicalTrials.gg
Status unknownNCT02996838Updated May 21, 2019

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

A Phase 1 interventional study of TQ-B3234 in Advanced Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To study the pharmacokinetic characteristics of TQ-B3234 in the human body, recommend a reasonable regimen for subsequent research.

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological documentation of Advanced solid tumors,such as Malignant Melanoma,Colorectal Cancer,Pancreatic Carcinoma,Thyroid Carcinoma
  • Lack of the standard treatment or treatment failure
  • 18-65 years, PS:0-1, of more than 3 months
  • Main organs function is normal
  • Stop other previous chemotherapy drugs more than 4 weeks
  • Women of should agree to use and utilize an adequate method of (such as intrauterine device,contraceptive and condom) throughout treatment and for at least 6 months after study is stopped;the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment,and the patients required to be non-lactating;Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
  • Patients should participate in the study voluntarily and sign

Exclusion criteria

Exclusion Criteria:

  • Patients participated in other anticancer drug clinical trials within 4 weeks or Patients participating in other clinical trials now
  • Blood pressure unable to be controlled(systolic pressure>140 mmHg,diastolic pressure>90 mmHg). Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including ≥440ms)
  • Patients with non-healing wounds or fractures
  • Patients with drug abuse history and unable to get rid of or Patients with mental disorders
  • History of immunodeficiency
  • Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TQ-B3234

    TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: TQ-B3234

Interventions

  • DrugTQ-B3234

    TQ-B3234 p.o. qd

06

What researchers measure

Primary outcomes

  1. The maximum tolerated dose (MTD) of TQ-B3234

    Yes \]The highest dose at which no more than 33% of the subjects experience a dose-limiting toxicity (DLT) during treatment

    Time frame: 48 weeks

  2. The type of dose-limiting toxicity(ies) (DLT[s]) of TQ-B3234

    Subjects within 28 days after treatment appear the following toxicity reaction relate to the drug :III °or above of non-hematological toxicity,IV°hematological toxicity ,Neutropenia associated with fever

    Time frame: For 4 weeks for DLTs

  3. Pharmacokinetics of TQ-B3234 (in whole blood):Peak Plasma Concentration(Cmax)

    Peak Plasma Concentration(Cmax),Cmax in ng/mL.In the study of single-dose, full PK profiles will be obtained at H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H34/H48/H72/H96/H120/H144(H means Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D8/D15/D21/D22/D23/D25/D28(D means Day)

    Time frame: up to 28 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  4. Pharmacokinetics of TQ-B3234 (in whole blood):Peak time(Tmax)

    Peak time(Tmax),Tmax in h.In the study of single-dose, full PK profiles will be obtained at H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H34/H48/H72/H96/H120/H144(H means Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D8/D15/D21/D22/D23/D25/D28(D means Day)

    Time frame: up to 28 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  5. Pharmacokinetics of TQ-B3234 (in whole blood):Half life(t1/2)

    Half life(t1/2),t1/2 in h.In the study of single-dose, full PK profiles will be obtained at H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H34/H48/H72/H96/H120/H144(H means Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D8/D15/D21/D22/D23/D25/D28(D means Day)

    Time frame: up to 28 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  6. Pharmacokinetics of TQ-B3234 (in whole blood):Area under the plasma concentration versus time curve (AUC)

    Area under the plasma concentration versus time curve (AUC), AUC in ng.h/mL.In the study of single-dose,full PK profiles will be obtained at H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H34/H48/H72/H96/H120/H144(H means Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D8/D15/D21/D22/D23/D25/D28(D means Day)

    Time frame: up to 28 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  7. Pharmacokinetics of TQ-B3234 (in whole blood):Clearance(CL)

    Clearance(CL),CL in L/h.In the study of single-dose,full PK profiles will be obtained at H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H34/H48/H72/H96/H120/H144(H means Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D8/D15/D21/D22/D23/D25/D28(D means Day)

    Time frame: up to 28 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: each 56 days up to intolerance the toxicity or PD (up to 24 months)

07

Study locations

1 of 1 sites recruiting
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
    Recruiting
    • Xiubao Ren, doctor · Contact
    • Zhao Yan, pharmacist · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2017 (actual). Primary completion is estimated for Dec 2020, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2016
First posted
Dec 19, 2016
StartActual
May 11, 2017
Primary completionEst.
Dec 2020
CompletionEst.
Dec 2020
Last update
May 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02996838
Responsible party
Sponsor
First posted
Dec 19, 2016
Start date
May 11, 2017
Primary completion
Dec 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
May 21, 2019

Study contacts

Xiubao Ren, doctor
Contact
rwziyi@yahoo.com
022-23340123
Zhao Yan, pharmacist
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion